Bonviva, also known by its generic name ibandronate, is a prescription medication used primarily in the treatment and prevention of osteoporosis in postmenopausal women. It belongs to a class of drugs known as bisphosphonates, which work by inhibiting the activity of cells that cause bone loss, thereby increasing bone mass and reducing the risk of fractures. Bonviva is distinctive in its dosing options, offering both a monthly oral tablet and a quarterly intravenous injection, providing flexibility in administration based on patient preference and medical advice. By slowing bone loss and increasing bone density, Bonviva helps to maintain strong bones and reduce the likelihood of fractures, a common and serious complication of osteoporosis.